open access

Vol 76, No 1 (2018)
Original articles
Published online: 2017-09-13
Submitted: 2017-05-08
Accepted: 2017-07-11
Get Citation

CHA2DS2-VASc score predicts contrast-induced nephropathy in patients with ST-segment elevation myocardial infarction, who have undergone primary percutaneous coronary intervention

Gokhan Cicek, Ersin Yıldırım
DOI: 10.5603/KP.a2017.0177
·
Kardiol Pol 2018;76(1):91-98.

open access

Vol 76, No 1 (2018)
Original articles
Published online: 2017-09-13
Submitted: 2017-05-08
Accepted: 2017-07-11

Abstract

Background and aim: We aimed to investigate the predictive value of the CHA2DS2-VASc score in the development of contrast-induced nephropathy (CIN). Methods: A total of 2972 patients who had been diagnosed with ST elevation myocardial infarction (STEMI) and who had undergone primary coronary angioplasty were included in the study. The patients were divided into three groups according to the CHA2DS2-VASc score, i.e.: low risk (1 point), intermediate risk (2 points), and high risk (≥ 3 points). The groups were followed with regard to CIN development. Results: The median CHA2DS2-VASc score was significantly higher in the CIN(+) group compared to the CIN(–) group (3 vs. 2, p < 0.001). The rate of CIN was 3.32-fold higher (OR 3.32, 95% CI 1.98–5.55, p < 0.001) in the high-risk group (CHA2DS2-VASc ≥ 3) compared to the low-risk group (CHA2DS2-VASc = 1). Age (OR 1.25, 95% CI 1.14–1.36, p < 0.001), female gender (OR 1.52, 95% CI 1.23–1.89, p < 0.001), hypertension (OR 1.50, 95% CI 1.265–1.78, p < 0.001), peak cre¬atinine kinase-MB (OR 1.15, 95% CI 1.10–1.21, p < 0.001), and the Killip score > 1 (OR 4.25, 95% CI 3.10–5.82, p < 0.001) were found to be independent predictors for CIN development. Conclusions: The CHA2DS2-VASc score is an independent and strong predictor of CIN development in patients with acute STEMI.

Abstract

Background and aim: We aimed to investigate the predictive value of the CHA2DS2-VASc score in the development of contrast-induced nephropathy (CIN). Methods: A total of 2972 patients who had been diagnosed with ST elevation myocardial infarction (STEMI) and who had undergone primary coronary angioplasty were included in the study. The patients were divided into three groups according to the CHA2DS2-VASc score, i.e.: low risk (1 point), intermediate risk (2 points), and high risk (≥ 3 points). The groups were followed with regard to CIN development. Results: The median CHA2DS2-VASc score was significantly higher in the CIN(+) group compared to the CIN(–) group (3 vs. 2, p < 0.001). The rate of CIN was 3.32-fold higher (OR 3.32, 95% CI 1.98–5.55, p < 0.001) in the high-risk group (CHA2DS2-VASc ≥ 3) compared to the low-risk group (CHA2DS2-VASc = 1). Age (OR 1.25, 95% CI 1.14–1.36, p < 0.001), female gender (OR 1.52, 95% CI 1.23–1.89, p < 0.001), hypertension (OR 1.50, 95% CI 1.265–1.78, p < 0.001), peak cre¬atinine kinase-MB (OR 1.15, 95% CI 1.10–1.21, p < 0.001), and the Killip score > 1 (OR 4.25, 95% CI 3.10–5.82, p < 0.001) were found to be independent predictors for CIN development. Conclusions: The CHA2DS2-VASc score is an independent and strong predictor of CIN development in patients with acute STEMI.
Get Citation

Keywords

CHA2DS2-VASc score, contrast-induced nephropathy, acute ST-segment myocardial infarction, percutaneous coronary intervention

About this article
Title

CHA2DS2-VASc score predicts contrast-induced nephropathy in patients with ST-segment elevation myocardial infarction, who have undergone primary percutaneous coronary intervention

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 76, No 1 (2018)

Pages

91-98

Published online

2017-09-13

DOI

10.5603/KP.a2017.0177

Bibliographic record

Kardiol Pol 2018;76(1):91-98.

Keywords

CHA2DS2-VASc score
contrast-induced nephropathy
acute ST-segment myocardial infarction
percutaneous coronary intervention

Authors

Gokhan Cicek
Ersin Yıldırım

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl